Home / Transcripts / CeriBell, Inc. (CBLL) · February 24, 2026

CeriBell, Inc. (CBLL) Earnings Call Transcript

February 24, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 56 min

Earnings Call Speaker Segments

Brian Johnston executive
#1

Hello, everyone, and welcome to today's call. Joining me from Ceribell are Jane Chao, our Co-Founder and Chief Executive Officer, and Scott Bloomberg, our Chief Financial Officer. Earlier today, Ceribell issued a press release with its financial results for the quarter and year ended December 31, 2025. You can find that press release in the Investor Relations section of the company's website. Before we begin, please note that during this call, management will make remarks containing forward-looking statements under federal securities laws, and these statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. During this call, anything said about what we expect or predict for upcoming events, outcomes, or results counts as a forward-looking statement. Such statements carry significant risks and unknowns that might make what actually happens or what we actually achieve diverge substantially from what these forward-looking statements anticipate or suggest. So please don't lean too heavily on them. A description and list of the risks and uncertainties tied to our business can be found in the Risk Factors section of the public filings we make with the Securities and Exchange Commission, among them the quarterly report on Form 10-Q that we filed with the SEC on November 4, 2025. The information shared on this conference call is time-sensitive and holds true only as of today's live broadcast, February 24, 2026. Except where the law demands it, Ceribell disclaims any intention or obligation to update or revise financial projections or forward-looking statements, whether as a result of new information, future events or otherwise. With that said, I'll hand the call over to Jane.

Xingjuan Chao executive
#2

Thanks, Brian. Good afternoon, everyone, and thanks for being with us on the call covering our fourth quarter and full year 2025 results. For Ceribell, 2025 proved to be an exceptional year, as we deepened our presence in the core seizure market while substantially broadening our total addressable market, which in our view has increased from $2 billion to more than $3.5 billion; we did this while posting strong financial results, generating fast revenue growth and keeping a solid gross margin profile. I'm happy to share that fourth quarter 2025 revenue came in at $24.8 million, which is 34% growth compared with the same period a year earlier. For the entire year, our top line came in at $89.1 million, which represents a 36% increase compared with 2024. When it came to gross margins, the fourth quarter delivered 87%, while the full year came in at 88%. As of December 31, our active account count was 647, meaning we brought in 32 net new accounts during the fourth quarter and 118 over the course of 2025. These results reflect how well our dedicated team executed with discipline, along with the reliable, recurring nature of our business model. Beyond driving rapid revenue expansion and enlarging our customer base, we also established a number of essential building blocks that form the groundwork for our vision. We know exactly what we're aiming for: point-of-care EEG should become the routine approach for handling seizures in acute care, and we want to use both our technology and our existing footprint so that EEG gets recognized as a new vital sign. The progress we made during 2025 has moved that vision substantially nearer to becoming real. If you want to become the standard of care, you have to show plainly that you're better than the way things are done today. Thanks to more than 140 peer-reviewed publications and abstracts, we feel we've solidly demonstrated that the Ceribell system can meet the unmet needs found in acute care, yet proof on its own won't get us there. For our ambitions to be realized, our technology has to be broadly accessible. During 2025, we rolled out a number of efforts designed to extend the advantages of our platform to every patient who needs it. To start, we expanded our commercial footprint, going from 35 territories during the latter half of 2024 to approximately 55 territories as of now. Early indicators suggest this spending is starting to deliver returns, since we have a particularly robust pipeline of accounts eager to take up our technology. Drawing on what we've learned, the way our investments are timed should begin lifting the pace of account wins in 2026, with an even greater uptick anticipated in 2027. Next, we demonstrated that we can raise utilization rates more quickly by methodically growing departments, creating protocols and pursuing other expansion efforts. Our strategy is clearly established, and since we've reached about 30% penetration in our existing customer base, there's substantial opportunity to grow further within those accounts. Also, we broadened the ways care sites can access us by securing FedRAMP high authorization, which made all 170 hospitals in the VA system eligible. Following a thorough pilot that went extremely well, the VA has made a commitment to expand across the system. Initial accounts went live during Q4 of 2025, and we look forward to bringing on additional ones over the first half of 2026. In closing, once the FDA granted clearance for our seizure detection products for neonate and pediatric patients, our addressable core seizure market increased by approximately $400 million. With this wider age range, we expect to bring accounts on board faster and go deeper into the installed base we already have, which covers over 600 hospitals. Let me spend a few minutes discussing the neonate market. Inside the NICU, seizures are the most common neurological emergency, and guidelines strongly support using EEG. Even so, traditional practice falls short in caring for these newborns, because EEG capacity is limited and epileptologists are scarce; in this patient group, 90% of seizures are nonconvulsive, and if physicians base a seizure suspicion purely on observation, they are mistaken more than 70% of the time; the fallout from that is huge. Evidence indicates that when seizures add up to roughly sixty minutes, you see a 15% reduction in scores for cognition and language development — a difference big enough to push a child from typical neurological functioning into permanent disability. Studies also demonstrate that for every hour treatment is postponed, the length of a seizure may multiply by two. If a seizure is recognized sooner and therapy is started earlier, doctors are able to significantly reduce how long a patient spends seizing, and that can genuinely change the course of that patient's development in a positive way. One recent example involved a 2-week old infant who came in with short episodes of unusual movement after several hours. The clinical team thought it might be seizure, but an EEG was required to confirm the diagnosis. Within 10 minutes our neonatal head cap was set up, and seizure was confirmed a few minutes afterward. The infant was quickly sent for imaging, which revealed cerebral venous sinus thrombosis, a stroke brought on by a blood clot that can be devastating absent early treatment. Armed with this information, the care team could treat the patient promptly and confidently. I'm glad to report that the infant is doing well today. After treatment, the clot has nearly completely resolved and seizures have not recurred. This story shows how the Cereal system can alter the trajectory of care within minutes, especially for these vulnerable patients. This is merely a single example among numerous similar accounts. Those initial clinical results, combined with leadership's understanding that newborns fall into certain of the most lucrative DRG reimbursement categories, have built up steam across the commercial pilot we are still running. Our view is that point-of-care EEG should be within reach for every NICU, and we intend to make that happen at the earliest opportunity. We are eager to bring this product to market in Q2, at which point we anticipate moving out of the pilot phase and into a complete commercial launch. With the larger sales force we now have, along with FedRAMP authorization and FDA clearance covering neonatal and pediatric patients, the groundwork for our main seizure business is now solid, which sets us up for a promising 2026; in our view, we've penetrated under 4% of a $2.5 billion core seizure market, and plenty of room to grow lies in front of us. Looking toward 2026, the path to achieving our ambition of becoming the standard for seizure detection in acute care has never looked clearer. Let's now shift to the second horizon of our vision: making EEG a new vital sign. Our belief is that one unified platform capable of distinguishing among the most prevalent and meaningful neurological abnormalities affecting acute care patients might radically transform the treatment paradigm. In the same way that individuals suffering from chest pain get an EKG, we envision a future in which any patient showing signs of altered mental status is given Ceribell as standard protocol. Over the last 3 months, we hit breakthrough milestones that put us in position to provide a complete neuromonitoring platform for acute care; in December 2025, we obtained FDA 510(k) clearance for our delirium algorithm, which makes the Ceribell system the first and only device cleared by the FDA for delirium detection and continuous monitoring. Then, in January 2026, we announced that the FDA had granted breakthrough device designation for monitoring LVO stroke among hospitalized patients. We hit both of those regulatory milestones earlier than planned. Let me start with delirium, since the need for objective monitoring there is clear. Sometimes called acute brain failure, it affects over 30% of ICU patients.

Xingjuan Chao executive
#3

In the ICU, if a patient has delirium, each day brings a mortality risk that is 10% greater, and should delirium occur during intensive care, the likelihood of later developing dementia rises by no less than 60%. Today, the way delirium gets diagnosed relies on a nursing protocol based on behavior. That approach is subjective, it places a heavy burden on staff, and it yields only a binary answer. Because this diagnostic tool has such limitations, tracking delirium accurately over time simply cannot be done. Consequently, judging how well management tasks are working and tweaking them on the fly becomes difficult; we think our continuous monitoring solution addresses this significant unmet need and simultaneously eases the load on nurses. On top of the obvious standalone demand for a delirium monitoring solution, the synergistic value this new technology brings together with our existing platform has us excited. There is a strong interrelation between seizures and delirium; the two can look alike when they present, yet their treatment paths are biometrically opposed. Among first-line medications for status epilepticus is one of the agents most likely to induce delirium. Adding further complexity, 48% of patients with seizures go on to experience delirium, while 42% of delirious patients show seizure or seizure-like abnormalities. We think that if you bring delirium monitoring together with seizure monitoring on one platform, in a way that fits together smoothly, you'll draw in patients you haven't reached before and get more of the people we already treat to use it. As we look ahead to 2026, our plan is to run a pilot that homes in on which patient groups to target, makes the workflow as efficient as possible, sharpens how we talk about the product commercially, and gathers clinical evidence. Alongside that, we're going after a new technology add-on payment, known as NTAP, to lend support to adoption. We're beyond thrilled to be the first company into what we see as a $1 billion greenfield market, a space where there is currently no other FDA-cleared monitoring device sold commercially. We think we can get this technology into the market fast and with little friction, because we already have an installed base and a sales organization in place. Those combined strengths should pave the way toward a full commercial launch that we anticipate happening in Q4 of 2026 or Q1 of 2027. Now, the last area I want to discuss is stroke. In our eyes, receiving breakthrough device designation from the FDA makes it clear that our algorithm for monitoring LVO stroke has real potential to save lives and is technically workable. When it comes to LVO patients, each minute that is saved translates into roughly an additional week of living without disability. And yet, for patients whose strokes happen while they are already admitted to the hospital, those warning signs frequently go unrecognized for hours at a time. Since the cognitive starting points of these individuals differ widely and they frequently are under sedation, on breathing tubes, or healing post-operation, recognizing the symptoms is extraordinarily challenging. Consequently, for patients in the hospital who experience a stroke, the rate of death during admission runs two to three times greater than for those whose strokes occur elsewhere. Across 2026, we will concentrate our work on producing clinical data and moving the LVL stroke detection effort through its regulatory steps. Together, seizure, delirium, and stroke constitute the foundation of our technology platform, which we think will prove essential for nearly all neurological patients receiving acute care. We look forward to sharing further details regarding the program in the quarters ahead. To wrap up, I take great pride in what our team achieved during 2025, and I'm excited about the road ahead. The year 2025 established both product and regulatory groundwork for growth we expect near term and far into the future. Patient access grew thanks to FedRAMP high approval along with 510(k) clearances covering pediatric and neonatal seizure detection. On top of that, we broadened our capabilities into a new, closely related disease state through regulatory clearance of our delivery algorithm. In our view, these wins have almost doubled our total addressable market, which we now put at $3.5 billion. In 2026, our plan is to sustain momentum by adding more accounts and increasing usage of the adult seizure offering, which remains the source of the bulk of our sales. We expect that once the pediatric and neonatal products are fully commercially launched, which is on the near horizon, there will be additional opportunity in the later part of 2026 as well as throughout 2027. Looking further ahead, our aim is to unlock still greater opportunity in 2027 and beyond, as over the coming quarters we put together a complete commercial strategy for delirium. We also see another encouraging avenue for growth in our algorithm for detecting LVO stroke. All of these efforts combined set the stage for a sweeping overhaul of how we operate, letting us go after the major market opening in front of us using a single, deeply unified brain monitoring platform capable of changing how neurological conditions are treated. We've never been closer to achieving our goal of establishing EEG as a new vital sign, and our belief only strengthens that this platform will bring about real change — change for patients, change for providers, and in the end, change for Ceribell. At this point, I'll pass things over to Scott Berenberg, our CFO, to walk through our fourth quarter results along with our 2026 guidance.

Scott Blumberg executive
#4

Thanks, Jane, and hello everyone this afternoon. As Jane pointed out, we brought in $24.8 million in total revenue for Q4 of 2025 — that's up 34% from $18.5 million in the same quarter of 2024. Growth was mainly fueled by broader uptake of the Ceribell system among both new and existing accounts. Product revenue came to $18.8 million in the fourth quarter of 2025, marking a 33% rise from $14.1 million in Q4 of 2024. Subscription revenue reached $6.0 million for the fourth quarter of 2025, a 37% gain from $4.4 million in the fourth quarter of 2024. All in all, we felt good about the ongoing expansion in active accounts and headcount purchasing trends during Q4. We closed out 2025 with 647 hospitals as our active account base, which means 32 accounts were added in Q4. We managed this even though our strategy was to steer clear of launches during the year's final weeks. Among the Q4 launches were a modest number of accounts tied to the VA system expansion we announced earlier. We expect more VA accounts to launch in upcoming quarters. We also observed higher account utilization in Q4, which we think stems from both our clinical account management team's work and the usual seasonal trend of greater usage during winter months when IT census runs higher; across all of 2025, total revenue hit $89.1 million, which is 36% growth compared with 2024. Product revenue for the entire year of 2025 was $67.3 million, up 34% versus 2024, while subscription revenue was $21.7 million, up 41% versus 2024. Gross margin in the fourth quarter of 2025 came in at 87%, versus 88% a year earlier. For the whole year, gross margin was 88%, compared with 87% in 2024. The Q4 decline stems from a partial-quarter effect of our shift to using inventory acquired after higher tariffs took effect on goods made in China. Thanks to our work to soften the present tariff situation — including our fully operational Vietnam manufacturing line and efforts to bring manufacturing costs down — we anticipate margins landing in the mid-80% range all through 2026; that projection doesn't factor in any effect from Friday's Supreme Court ruling or any future policy shifts. Total operating expenses for the fourth quarter of 2025 were $36.2 million, up 24% from $29.1 million in the fourth quarter of 2024. Noncash stock-based compensation expense totaled $3.3 million in the fourth quarter of 2025. For the full year 2025, total operating expenses were $136.7 million, versus $96.5 million for all of 2024, which works out to a 42% increase. Full year 2025 operating expenses included $12.2 million in noncash stock-based compensation. Higher operating expenses for Q4 and the entirety of 2025 came mainly from spending on our commercial team, adding staff to keep pace with business expansion, legal costs, and the costs of being a publicly traded company. For Q4 2025, net loss came to $13.5 million, equal to a loss of $0.36 per share, versus a loss of $12.6 million, or $0.40 per share, in Q4 2024. Loss per share for Q4 2025 was calculated using an average weighted share count of 37.2 million shares. Full year 2025 net loss reached $53.4 million, or a loss of $1.46 per share, compared with a loss of $40.5 million, or a loss of $3.39 per share, in 2024. Cash, cash equivalents and marketable securities stood at $159.3 million on December 31, 2025. Now let's discuss what we expect for 2026. We anticipate total revenue for the full year 2026 landing between $111 million and $115 million, which would mean annual growth of 25% to 29% over 2025. As Jane noted, at present we expect to move ahead with a complete launch of our neonate and pediatric products during Q2 of this year. Although we do think the sales cycle could be shorter at hospitals already using the Ceribell system for adult patients, our belief is that in most cases a multi-month sales process will still apply, encompassing contracting, workflow design and training. By the end of the year, we expect to build commercial traction at a number of hospitals, yet because of launch timing and anticipated sales cycles, the effect on 2022 revenue will probably be modest. Our aim is to make the pediatric and neonate products significant revenue contributors in 2027 and beyond. Last, our cash position stays strong, with cash, cash equivalents and marketable securities of $159 million as of December 31. We intend to deploy capital selectively into incremental R&D and commercial infrastructure investments so we can seize our untapped market opportunity and sustain rapid long-term revenue growth; even so, we stay dedicated to our goal of reaching cash flow breakeven with cash on hand; given our gross margin profile, recurring revenue model and high customer retention rates, we are still confident in our capacity to achieve that; and with that, I'll hand the call back to Jane.

Xingjuan Chao executive
#5

Appreciate it, Scott, and I'm grateful to everyone for spending part of your day with us. To wrap up, our results for 2025 leave us quite encouraged, and we think that puts us in a strong spot to keep expanding throughout 2026 and afterward. Let me pause briefly to express gratitude to everyone at Ceribell for their ongoing commitment to the goal of establishing EEG as a new vital sign. At this point, I'll hand things back to the operator so we can take questions. Operator?

Travis Steed analyst
#6

Nice work on the quarter and everything moving forward in the pipeline. Perhaps I'll begin with the 2026 guidance. When you look at dollar growth alone, it's around $24 million, which is approximately what we achieved in 2025, yet your TAM has doubled. You've got accelerating center adds coming in the back half of the year, and utilization keeps rising. So I just wanted to get a handle on the various moving pieces and assumptions behind 2026.

Scott Blumberg executive
#7

Travis, let me first say that our guidance philosophy remains the same. Like we've always said, we truly recognize the importance of hitting the numbers we set out — the necessity of delivering on what we put forward. So we've incorporated a suitable degree of conservatism into the model. Regarding the sequential growth, I believe it's worth recognizing that last year's guide matched this year's guide. And given that the philosophy remains unchanged, we see room for upside provided we function according to the principles we anticipate, with the investments we've made. When it comes to the pipeline, like we said, we genuinely expect it to begin gaining traction near the end of this year and further into 2027. So there's a bit of neonate included in Q4, though it's relatively modest. But we believe that as we head into 2027, it could contribute next year.

Travis Steed analyst
#8

All right, and could you perhaps go into a bit more detail about the commercial strategy for delirium, and help me grasp how you'd go about building that up? Are you going to begin seeing possible gains when it comes to adding accounts and getting deeper into accounts because of that? Or does the commercial plan for delirium involve a somewhat different sales motion?

Xingjuan Chao executive
#9

Yes. We're currently in talks with a number of accounts regarding the commercial pilot. And most of those accounts are ones we already work with, along with a few new ones too. So when it comes to the commercial pilot, our main emphasis really is on validating our clinical impact in the real world; so those conversations with accounts will center on which patient population is the ideal target, the workflow, the way to measure impact, and also producing case studies and clinical evidence. And so this piece, as I said before, comes mostly from accounts we already have. We also expect that to show up at least over the short term, where delirium can generate financial and commercial impact too. It's going to lean more toward deepening utilization within the accounts we already serve; and within that, we see 2 drivers. The first is delirium by itself — we're bringing in a new patient population. That isn't seizure. And the second driver we see is a substantial synergistic interaction that exists between delirium and seizure, as I noted during the earnings call. So we could see that driver go deeper into the seizure population as we bring in delirium as well.

Lilia-Celine Lozada analyst
#10

Lilly here, filling in for Robbie. When we look ahead to 2026, could you walk us through the growth levers you consider most important that you're activating during this year? You mentioned faster account additions, I believe. So how do you plan to weigh that against keeping utilization rising? And in your view, which levers in the model hold the greatest upside potential for this year?

Scott Blumberg executive
#11

I'll speak to the mechanics of those levers, and perhaps, Jane, you could weigh in on the drivers. Our adult user market still rests on 2 primary drivers, and those haven't changed: how quickly accounts are added, plus same-store growth. Regarding account additions, our expectation is that 2026 brings more new accounts than 2025 did, which stems from the approach we set out a year ago, among them growing the sales team, securing FedRAMP approval, and momentum from excitement surrounding neonate and pediatric. As for what we can do inside existing accounts, penetration across our account base sits at roughly 30%, and we have multiple strategies designed to raise that figure, such as training additional physicians, reaching new departments, and rolling out protocols. We assembled a strong campaign to support those initiatives, and there's substantial room for us to keep advancing it.

Xingjuan Chao executive
#12

Yes, and building on Scott's points, we have a clear playbook for bringing on accounts and for boosting utilization. Let me highlight a few perhaps new levers for 2026. When it comes to acquiring accounts, we're placing fresh emphasis on winning deals at the hospital system level. That means concentrating on large systems along with small and medium-sized ones. Rather than the historical approach where a territory manager aimed to close 1 or 2 accounts, how do we speed up closing an entire system — a 10 hospital system, for instance? So we could view that as additional growth leverage near term and long term; on the utilization side, we began more systematic departmental expansion during 2025, and the impact from that expansion has been consistent. It might mean moving into the emergency department, into another ICU, or occasionally onto the floor. So we intend to build further on what was established in 2025 and anticipate that departmental expansion will likewise drive utilization.

Lilia-Celine Lozada analyst
#13

Excellent, that's quite useful. Now, turning to a second question: how ought we to consider spending before launches across all of these additional indications? Once you add pediatric, delirium, and LVO stroke, the TAM grows substantially. So does a substantial amount of investment need to happen in advance on the sales force and commercial infrastructure side? Or do you believe you can mostly build on what's already in place?

Scott Blumberg executive
#14

Our plan is to mostly build on the commercial infrastructure we have. What makes our platform attractive is that the call point stays the same. The platform stays the same. All that's really needed is to train the reps on the additional indications and get that message across to the customers. Naturally, some upfront investment tied to a product launch will be required on the marketing and market development side. As for the core infrastructure, though, we anticipate fairly modest investments in that area.

Brandon Vazquez analyst
#15

First, I'd like to zero in on what was said regarding the neonate launch. Perhaps we could take a bit more time on the commercial rollout and really examine it. As we've discussed previously, I believe certain accounts you're already present in can now be opened up to that neonate population, or the NICU; and frankly, it seems somewhat late that benefits won't begin appearing until roughly late in Q4; so could you explain just why a few quarters are needed before we start seeing those in accounts where you already have a presence, so everyone is clear on when those benefits will begin scaling up more significantly.

Xingjuan Chao executive
#16

Yes. Thank you, Brandon; so perhaps we should concentrate on the neon NICU expansion within current accounts. I believe that's what you're getting at. So roughly 200 Level 3 and Level 4 NICUs exist among our current accounts. Considering the timing, our plan is to launch during Q2. Despite already being inside this hospital, expanding into a new department means the hospital must obtain an extra recorder along with the clarity system intended for neonatal seizure detection; so that typically means going through a committee and then another committee. We anticipate that sales cycle being shorter compared to acquiring a completely new account, yet it still requires several months. And once that departmental expansion at the account happens, discussions around workflow and patient population will follow. From what we've experienced, that usually takes a couple of months too. So when you work through the timing, that explains why a Q2 launch would produce financial or commercial impact in Q4.

Brandon Vazquez analyst
#17

All right. So perhaps I can connect that to a few modeling questions for Scott. When we consider extra recorders and items along those lines, could you just reset and level set the way we ought to be modeling part of that? What's the right way to think about where that shows up in the model, say ASPs and similar items? Then maybe I can also attach a modeling question here from the earlier one. What's the right way to think about — I'll put it more pointedly regarding the OpEx line. What's the right way to think about '26? Is that a source of leverage? Or is it the case that OpEx must expand at a faster rate than your overall revenue growth?

Scott Blumberg executive
#18

Sure; regarding the commercial side for neonate, our model has us charging an extra subscription cost when the neonate product gets adopted. For someone who's already an adult customer, the cost of adopting neonate isn't 2x, though it exceeds that of simply being an adult customer; and we'd anticipate that the headbands, which follow a comparable pricing model yet carry a somewhat greater price, would be included as well. The manner in which it shows up in the top line wouldn't necessarily be a shift in the count of accounts, apart from children's hospitals that adopt specifically for neonate, but rather growth in both product and subscription revenue via our installed base. When it comes to OpEx, although we don't give specific guidance, I'd gladly offer a bit of color by walking through the various functions to assist with your modeling; regarding sales and marketing, we think we mostly have the commercial infrastructure in place to deliver on our 2026 guidance. We'll be selectively investing in opportunities to drive growth in 2027 and beyond throughout the year. That covers the previously discussed regional system function along with expansions within the CAM work to support the growing account base. And then, as I said earlier, there may be some extra investments tied to market development activities connected to the launch of our new products. But given our platform and our existing infrastructure, we don't anticipate materially increasing the size of the sales or to support those functions. On R&D, we see a great deal of opportunity ahead of us, and so we're going to keep investing in R&D. We expect a decrease in the growth rate in R&D spend this year, but we do expect R&D growth to be outsized compared to the rest of the department given what we have ahead of us; and then on G&A, our infrastructure on G&A is largely in place. Thus, we anticipate significant leverage will show up there. Still, it's important to point out that given how our patent infringement lawsuit against Natus is proceeding, the expenses tied to IP litigation are bunched mostly into the first six months of this year. As a result, I would anticipate some modest uptick in G&A across roughly the next 2 quarters. One last point on OpEx: it aligns with what you're seeing from our competitors, and we anticipate noncash stock-based compensation expense will rise over the course of the year as we keep shifting toward the compensation practices of a public company. So I hope that helps. Overall, I do anticipate our OpEx will ease in 2026. You began to see a bit of that during Q4, when we posted the smallest year-over-year growth rate in OpEx we've had. We do want to put our capital to work strategically to fuel long-term growth for the business. Yet whenever we make investment choices, we remain focused on our North Star, which is reaching breakeven with the cash we have on hand, and we're extremely confident we can get there.

Josh Jennings analyst
#19

Brian here, filling in for Josh. Regarding the revenue guidance: does the VA expansion figure into your sales projections for this year, and if so, how? Also, could you walk through the specific tariff assumptions behind the mid-80s gross margin guidance for the year?

Scott Blumberg executive
#20

Yes. So the VA is baked into our guide when it comes to the expansion committed to last year, though additional expansion is not baked into the guide. And we'll be chasing that through the government budgeting cycle, which is probably going to come up for discussion around Q3, for late '26 and 2027 impact, potentially above our guide. On the tariff assumptions: clearly, there's been a great deal of change over the past couple of days regarding what our policies are. None of those changes are contemplated by our guide. So what our guide does include is the shift from the prior tariff rates in China since 2018 of roughly 25% to the pre-Friday tariff rates, which in aggregate were around 55% in China, offset by our move in part to Vietnam with lower tariff rates, along with some reductions we've achieved over the past couple of years on our product manufacturing costs; and absent any benefit from the potential impact of Friday's Q4 decision, we have confidence that we'll maintain margins in the mid-80% range throughout the year.

Analyst analyst
#21

All right. Then a quick follow-up, if I may. Regarding the NTAP for delirium, do you mean you're ready to submit for the NTAP, or the NTAP that could take effect this October? Or would this more likely be a decision in 2027 for you?

Xingjuan Chao executive
#22

Yes; we filed the NTAP late last year. Should we get it, it would take effect this October in 2026; and CMS would issue the preliminary decision in April, so within a couple of months.

Bill Plovanic analyst
#23

To make things clear, over the last 2 quarters your operating losses have gone down each quarter. Based on the thorough guidance you gave, leaving out IP litigation expenses, that pattern would keep going all through 2026. Then we — I believe our model assumes you reach positive adjusted EBITDA in Q4 of '26. Any reactions to those points?

Scott Blumberg executive
#24

I'd rather not say anything specific past the guide. What I can tell you is that the investment — the infrastructure currently in place is enough to support us into 2026, though our thinking always extends 2, 3, 4 years out. So when the investments start showing results by turning into faster growth, we genuinely want to put in more money to fuel above-market expansion in the later years of the model. We constantly watch closely what that does to our total cash position. Time to breakeven doesn't get as much of our focus, but we need to make sure we're growing as much as possible without jeopardizing our capacity to breakeven.

Bill Plovanic analyst
#25

All right. And regarding delirium, is this mostly just a case of seeing greater usage? Or — I realize you're working toward the add-on — but do you believe you could truly command a higher price? And after that, how would deploying that look alongside the new algorithm? What I'm asking is, is it simply a cloud-based download? Or must you go out into the field and install the updated algorithm? How exactly does that rollout work?

Xingjuan Chao executive
#26

Yes. Thanks, Bill. When it comes to what we'd charge for delirium, we're a bit early to say anything, and that's something the commercial pilot will teach us as we adjust more effectively to what the market demands; charging is certainly possible for the algorithm and the head been both, though those choices are ones we'd prefer to finalize at a later point. As for the way we get the algorithm in and deploy it, that part is fairly simple: we're able to push remote updates to the recorder's firmware and to the portal alike, which lets us activate delirium for our current users and current recorder from a distance pretty quickly.

Bill Plovanic analyst
#27

And beyond that, do you expect any added costs tied to handling this in-house, like staff time spent going through the data and those reports, or anything along those lines?

Xingjuan Chao executive
#28

Like Scott said, when it comes to commercialization, our current sales force is what we rely on. Where R&D and ops are concerned, a bit of extra spending will be necessary since the portal and the device keep getting more complicated, though that amount isn't large. We'll put money into marketing too, plus market development and generating clinical evidence. Still, when it comes to rolling out the algorithm, there's no substantial jump in OpEx.

Marie Thibault analyst
#29

It's good to see the new account additions move up once more on a sequential basis this quarter; and I caught what you said about account adds speeding up in '26 and '27. My guess is that part of this ties directly to the improved rep productivity that is now coming online. But I was hoping to get some clarity on that acceleration remark? Does it represent an acceleration from the low 30s, which is where we stand today, or from the mid-20s, which is where we stood earlier in 2025? And should we anticipate that this keeps building across the year, considering when some of these newer reps you brought on roughly 12, 18 months ago came aboard?

Scott Blumberg executive
#30

Taken at face value, that remark applied specifically to the full year. So my understanding is we added 118 during 2025, and therefore we anticipate adding more than 118 in 2026. Quarter-to-quarter there will be some lumpiness. It isn't completely linear, particularly given the new health system strategy, under which we anticipate purchase orders arriving in boluses. So I would not anticipate it being fully linear. Even so, the reps do become progressively better. What history has shown us is that reps do become progressively more and more productive, moving from year 1, when they begin to contribute, into year 2, when they hit something close to their peak productivity. And so, as more reps age into greater productivity over the course of the year, we anticipate a broad trend of acceleration.

Marie Thibault analyst
#31

Okay, that's quite useful, Scott. You also mentioned a topic I'd like to probe, namely the effort to make sales across the whole health care system — perhaps a sort of enterprise-level strategy. Give us some more detail on what happens behind the scenes there. Are we beginning to observe that in accounts yet? Or does all of it still lie ahead? I suppose I'm somewhat uninformed about how recently this was launched.

Xingjuan Chao executive
#32

Right. Last year we observed a few senior territory managers, and we achieved a very meaningful win selling into this small, midsized hospital system. The factors behind that success are, first, these senior TMs would frequently collaborate closely with the regional director and even the sales regional VP, since these systems often span different territories or different regions; that way we can build a coherent system-level strategy, rather than concentrating on just 1 or 2 hospitals. Also, they begin engaging the key stakeholders, particularly administrators at the system level, and refine the value proposition at the system level rather than for a single ICU or a single ED. Given last year's success, we are broadening that model this year. So we are fairly confident that we can extend further the success we witnessed.

Jeffrey Cohen analyst
#33

We have a couple of questions. Can you provide any update on the patent dispute involving Natus — specifically where things stand and what impact it might have on expenses for 2026?

Xingjuan Chao executive
#34

I can address the procedural side. The discovery stage is where we currently are, and the preliminary ruling is scheduled for November 19. Ahead of that date, a full series of events will take place, and the complete set of milestones and the schedule can be found publicly on the ITC website.

Scott Blumberg executive
#35

Yeah, regarding expenses, from when we started this around Q3 of last year, the costs have come in fairly linear; given how litigation tends to go, we don't anticipate that staying linear; what we're observing is that during the heaviest part, the heart of the case, which is taking place now through Q2, we'd anticipate those expenses rising and then possibly easing in Q3 and Q4 as we get into the later phases, at least of this first half with the ITC.

Jeffrey Cohen analyst
#36

All right, understood. And then second — actually first — could you discuss the LVO indication and where it would be used, beyond the ICU, and also whether you're considering neuro and/or cardiac?

Xingjuan Chao executive
#37

Sure. LVO monitoring would be aimed at inpatients. A large number of these patients are in fact still in the ICU. So, once again, that's the same call point. Having said that, what we've found initially is that a notable share of patients experience stroke outside the ICU — for instance, on the floor or in telemetry monitoring units. On top of that, they receive even less training, or inadequate training, at the bedside nursing level when it comes to spotting stroke. So our expectation is that this would serve as a highly synergistic add-on alongside both seizure and delirium. As for your remarks about neuro versus cardiac, I don't entirely follow. Could you put that another way?

Jeffrey Cohen analyst
#38

When we're talking about most of those patients in the ICU, is it the neurologists who are handling the care, along with the equipment that's in use?

Xingjuan Chao executive
#39

Correct. When it comes to LVO, neurologists are certainly going to be part of it, though in that case you'd see more stroke neurologists rather than epileptologists. That said, what typically happens under the current standard of care is that if a nurse spots any stroke or potential symptoms that might signal a stroke, the stroke team will hurry to the bedside. So you'll certainly have at minimum a general neurologist, and frequently a stroke neurologist.

Elaine Cui analyst
#40

Elaine Cui speaking, standing in for Jason: regarding delirium, I wanted to ask whether you've kicked off the pilot launch, or begun any initial conversations with hospitals yet? If that's underway, would you mind giving us some detail — pardon me, a bit of color — about how the early progress is going and what you're learning?

Xingjuan Chao executive
#41

Sure. We've already begun talking with a fair number of accounts as part of the commercial pilot, and we don't anticipate any commercial pilot going live before Q2, since we're still working through making certain that each of the various algorithm software pieces is completely integrated. To add some color, the feedback we got initially was extremely favorable. Most intensivists are highly aware of delirium and the harm it can potentially inflict, and they're frequently rather frustrated that objective, continuous biomarkers for delirium don't exist. A further strong indicator is their recognition that a particular patient population shows a very high prevalence of both delirium and seizure. So the earlier hypothesis the physicians validated is that our device might be able to assist them in catching delirium sooner, because not every nurse has solid training, and the algorithm might help by giving them feedback so they know if they're on the correct path, and also genuinely assist them in telling seizure and delirium apart within that same population. Take one example: when a sepsis patient has altered mental status, 20%, 30% of them might have seizure, and then 40% might have delirium, even though in such a patient the symptoms look extremely alike — the person appears very confused. So the early feedback from the physicians, plus the nursing team and the administrators, has us quite encouraged.

Elaine Cui analyst
#42

Thanks for that detail. As a second question, could you tell us what you're anticipating for tech band pricing in the coming year? I realize you've already said something about neonate pricing, but when it comes to headband overall, are you planning to implement a price increase during this year?

Scott Blumberg executive
#43

Are you asking about this broadly, or specifically in connection with the delirium product?

Elaine Cui analyst
#44

Apologies — that was simply a general question.

Scott Blumberg executive
#45

Over the years, we've kept our pricing discipline quite strong, with ASPs holding steady. Regarding the macro environment, I'd say much remains uncertain — there are both headwinds and tailwinds when it comes to tariffs, how people comprehend them, and how businesses respond, plus certain strains facing hospitals. We look at each situation individually. Still, regardless of anything else, we anticipate keeping our pricing discipline extremely tight.

Xingjuan Chao executive
#46

Well, I appreciate everyone being here on this call. Once more, we feel a great deal of pride in what was achieved during 2025, and there's nothing that could make us more enthusiastic about 2026. Thanks to each of you.

Operator operator
#47

That concludes today's call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete CeriBell, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to CeriBell, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.